Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.

Mustafa Khasraw, Adrian Lee, Sally McCowatt, Zoltan Kerestes, Marc Buyse, Michael Back, Ganessan Kichenadasse, Stephen Ackland, Helen Wheeler

    Research output: Contribution to journalArticle

    22 Citations (Scopus)

    Fingerprint Dive into the research topics of 'Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.'. Together they form a unique fingerprint.

    Medicine & Life Sciences